November 23, 2021
3 min watch
Save
VIDEO: Orasis completing phase 3 presbyopia drop trial
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
BOSTON – Orasis Pharmaceuticals anticipates finishing its phase 3 program involving CSF-1 ophthalmic solution for treating presbyopia this year, President and COO Paul Smith said here at the American Academy of Optometry meeting.
“NEAR-1 and NEAR-2, together with our phase 2b study, will form a program in which CSF-1 has been studied in more than 700 patients,” he said.
Published by:
Sources/Disclosures
Collapse
Disclosures:
Smith reports being president and COO of Orasis.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.